- The company reaffirms its commitment to grow revenue and expand margins through the balance of the decade, while sustaining a flow of innovative medicines and deploying capital to create shareholder value.
- 2016 revenue is anticipated to be between $20.2 billion and $20.7 billion.
- Earnings per share for 2016 are expected to be in the range of $2.92 to $3.02 on a reported basis and $3.45 to $3.55 on a non-GAAP basis. Non-GAAP figures for 2016 exclude amortization of intangibles as well as continued integration costs associated with the Novartis Animal Health acquisition.
- The late-stage pipeline includes 9 potential new medicines or diagnostic agents in either Phase III development or submission stage.
- The company now expects 2015 earnings per share to be in the range of $2.28 to $2.33 on a reported basis. Expected 2015 non-GAAP earnings per share have been reaffirmed at $3.40 to $3.45.
"We've stayed true to our commitment to innovation, and it's paying off for patients and shareholders. Lilly continues to deliver on our financial commitments while advancing our pipeline and launching new medicines," said
Lechleiter added, "We enter 2016 in a position of strength anticipating continued growth. Our goal is to sustain the flow of valuable medicines from our pipeline to improve patients' lives and create value for shareholders."
"In 2016 we expect multiple regulatory actions across therapeutic areas including diabetes, oncology and immunology," said
Lilly also said 2015 earnings per share are now expected to be in the range of
2016 Financial Guidance
Earnings per share for 2016 are expected to be in the range of
2016 Expectations |
||
Earnings per share (reported) |
$2.92-$3.02 |
|
Exclusion of amortization of intangibles |
$0.41 |
|
Exclusion of |
$0.12 |
|
Earnings per share (non-GAAP) |
$3.45-$3.55 |
|
|
The company anticipates 2016 revenue between
Marketing, selling and administrative expenses are expected to be in the range of
The 2016 tax rate is expected to be approximately 20.5 percent on a reported basis and 22.5 percent on a non-GAAP basis. The expected 2016 reported tax rate includes the tax impact of integration costs associated with the
The following table summarizes the company's 2016 financial guidance.
2016 Guidance |
|||
Reported |
Non-GAAP |
||
Total Revenue |
|
|
|
Gross Margin % of Revenue |
Approx. 74% |
Approx. 77% |
|
Marketing, Selling & Admin |
|
|
|
Research & Development |
|
|
|
Other Income/(Expense) |
|
|
|
Tax Rate |
Approx. 20.5% |
Approx. 22.5% |
|
Earnings per Share |
|
|
|
Capital Expenditures |
Approx. |
Approx. |
|
Webcast of Conference Call and Investor Materials
As previously announced, investors and the general public can access a live webcast of the 2016 financial guidance conference call and investor materials through a link on Lilly's website at www.investor.lilly.com. The conference call will be held today beginning at
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and voluntarism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. F-LLY
This press release contains management's current intentions and expectations for the future, all of which are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "estimate", "project", "intend", "expect", "believe", "target", "anticipate" and similar expressions are intended to identify forward-looking statements. Actual results may differ materially due to various factors. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees that pipeline products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. The company's results may also be affected by such factors as the timing of anticipated regulatory approvals and launches of new products; market uptake of recently launched products; competitive developments affecting current products; the expiration of intellectual property protection for certain of the company's products; the company's ability to protect and enforce patents and other intellectual property; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals, including
________________________________________
Basaglar® (insulin glargine injection, Lilly)
Cialis® (tadalafil, Lilly)
Cyramza® (ramucirumab, Lilly)
Erbitux® (cetuximab, Lilly)
Forteo® (teriparatide of recombinant DNA origin injection, Lilly)
Humalog® (insulin lispro injection of recombinant DNA origin, Lilly)
Jardiance® (empagliflozin,
Portrazza™ (necitumumab, Lilly)
Strattera® (atomoxetine hydrochloride, Lilly)
Trajenta® (linagliptin,
Trulicity® (dulaglutide, Lilly)
Refer to: